Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma

Reinis, M.

Current Opinion in Molecular Therapeutics 9(3): 291-298

2007


ISSN/ISBN: 1464-8431
PMID: 17608028
Document Number: 609754
Favrille Inc is developing FavIld, a patient-specific immunotherapy combining tumor-specific idiotype protein and keyhole limpet hemocyanin, for the potential treatment of lymphoma. A phase III clinical trial in follicular B-cell non-Hodgkin's lymphoma is underway.

Document emailed within 1 workday
Secure & encrypted payments